Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>Tumor and anatomical changes during radiotherapy have been observed in stage III non-small cell lung cancer (NSCLC) from many previous studies. We hypothesized that a routinely scheduled adaptive radiotherapy would have clinical important dose benefits to lower the risk of toxicities, without increasing the tumor recurrences.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We retrospectively reviewed 92 consecutive patients with inoperable stage III NSCLC between November 2017 and March 2019. All eligible patients received simultaneously integrated boost (SIB) using intensity-modulated radiation therapy (IMRT). A mid-treatment CT simulation and a new adapted plan were routinely given after the first 20 fractions. The organs at risk (OARs) were delineated per RTOG 1106 atlas. Dose-volume histograms were quantitatively compared between the initial and composite adaptive plans. Logistic regression was applied to analyze the dose-response relationship. Clinical endpoints included symptomatic acute symptomatic RP (RP2) and esophagitis (RE2), local controland regional tumor control, and progression-free survival (PFS).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Sixty-four eligible patients received adaptive SIB-IMRT were consecutively included. The GTVs reduced by a median of -38.2% after 42 to 44 Gy in 20 fractions of radiotherapy. By adapting to tumor and anatomical changes, dosimetric parameters of OARs decreased significantly. The mean lung dose decreased by an average of -74.8 cGy, and mean esophagus dose was lower by 183.1cGy. We found grade 2 or higher acute RP in 11 patients (17.2%), and RE2 in 28 patients (43.8%). Commonly used lung and esophagus dose metrics were significantly associated with RP2 and RE2. The adaptation could reduce RP2 probability by 3%, and RE2 risk by 5%. Subgroups with higher OARs dose or larger tumor shrinkage may get more dose and toxicities benefits. The estimated median PFS was 12.5 months from the start of radiotherapy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>We demonstrated that the routinely adaptive SIB-IMRT strategy could significantly reduce the dose to surrounding normal tissues, potentially lower the associated acute RP and RE, without increasing the risk of tumor recurrences.</p>

Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: an Automatic Treatment Planning Study

The Therapeutic Value of Volumetric-Modulated Arc Therapy In Advanced Non-Small Cell Lung Cancer Primary Tumors: A Multicenter Retrospective Analysis Based On Propensity Score Matching And Comparison With Intensity-Modulated Radiotherapy

Dosimetric comparison of commonly used volumetric modulated arc therapy field arrangements based on flattening filter-free beams for synchronous bilateral breast carcinoma radiotherapy

Comprehensive dosimetric planning comparison for early-stage, non-small cell lung cancer with SABR: fixed-beam IMRT versus VMAT versus TomoTherapy

Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT

EP-1567: A Hybrid IMRT/VMAT Technique for the Treatment of Non-Small Cell Lung Cancer

A dosimetric evaluation of knowledge-based VMAT planning with simultaneous integrated boosting for rectal cancer patients.

Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study

Treating early-stage centrally-located non-small cell lung cancer with DCAT-SBRT in centers lacking the VMAT technique: a comprehensive study

Dosimetric Feasibility of Stereotactic Ablative Radiotherapy in Patients with Ventricular Tachycardia Using Intensity Modulated Proton Therapy

Lung sparing in MR-guided non-adaptive SBRT treatment of peripheral lung tumors

A Novel Integrated Vmat/Imrt Technique for the Treatment of Non-Small Cell Lung Cancer

Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?

Dosimetric Comparison of Postmastectomy Radiotherapy Plans for Synchronous Bilateral Breast Cancer, Including Regional Lymph Node Irradiation

Single isocenter versus dual isocenter treatment using flattening filter‐free and jaw‐tracking volumetrically modulated arc therapy for boot‐shaped lung cancer: Evaluation of dosimetric and feasibility

Isotoxic Investigation of 18F-FDG PET/CT-guided Dose Escalation with Intensity-Modulated Radiotherapy for LA-NSCLC

Approach and assessment of automated stereotactic radiotherapy planning for early stage non-small-cell lung cancer

Improving efficiency in the radiation management of multiple brain metastases using a knowledge-based planning solution for single-isocentre volumetric modulated arc therapy (VMAT) technique

Optimization of collimator angle combined island blocking with parked gap achieves superior normal tissue sparing in SBRT planning of multiple liver lesions

Dosimetric Evaluation of Different IMRT Treatment Plans for Non-Small Cell Lung Cancer

Investigate the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: A Comparison Between Photon and Proton Beam Therapy